The New York City startup scene generated its fair share of venture deals this month, the most notable being a $275 million oversubscribed round by a potential pharmaceutical powerhouse in stealth mode. Read on to see what else happened in October funding news.
#5, $53 million, October 1
Brightfield is a SaaS platform that provides market intelligence to companies that work with temps, consultants, freelancers and contractors. Its database helps organizations optimize their spending and structure their teams strategically. The company brought in $53 million in Series A funding to help large companies continue to leverage the gig economy.
#4, $55 million, October 8
RapidSOS is leveraging the internet of things to send data from connected devices to first responders. Information like location data, vehicle telematics and video footage can help emergency personnel respond faster and more strategically. The company secured a $55 million Series B round that will fuel its global expansion and drive data-sharing partnerships with applications and device-makers.
#3, $80 million, October 3
Unqork lets companies build their own enterprise software applications without using code. Instead, users just drag and drop features into place. The company closed an $80 million Series B round led by CapitalG, the venture arm of Google parent company Alphabet.
#2, $110 million, October 23
Fabric, formerly CommonSense Robotics, makes software and hardware for micro-fulfillment centers, which help retailers reduce transportation and labor costs as customers increasingly expect on-demand delivery. Clients can use Fabric’s platform and robotics at their own sites, or they can put their products in one of Fabric’s existing facilities. The company raised $110 million in Series B funding to build micro-fulfillment centers across the U.S.
#1, $275 million, October 28
Nuvation is a biotech startup operating in stealth and developing new, proprietary medications for cancer. Its founder David Hung was previously the CEO of Medivation, which created a widely used prostate cancer drug. Now, Nuvation contains seven oncology programs, each with drug development candidates. It raised $275 million in an oversubscribed Series A round.